Nektar and AstraZeneca entered into an exclusive global licensing agreement for two of Nektar's proprietary programs, Movantik and NKTR-119, in September 2009.
MOVANTIK (naloxegol) is the first FDA approved once-daily peripherally-acting mu-opioid receptor antagonist (PAMORA) specifically designed for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. In the Phase 3 clinical studies, MOVANTIK was administered as a once-daily tablet and was designed to block the binding of opioids to opioid receptors in tissues such as the gastrointestinal (GI) tract. MOVANTIK was developed using Nektar's oral small molecule polymer conjugate technology.
Nektar has an intellectual property licensing agreement with Allergan and is entitled to royalties on global sales of SEMPRANA.
Under the terms of an agreement between Nektar and Allergan, Nektar is entitled to receive royalties on the global sales of SEMPRANA for all indications. Allergan is developing SEMPRANA as a potential treatment for migraine. SEMPRANA is an orally inhaled version of dihydroergotamine (DHE), self-administered via Allergan''s proprietary Tempo® inhaler. A New Drug Application (NDA) for SEMPRANA is currently being reviewed by the U.S. Food and Drug Administration (FDA).
Nektar Proprietary PEGylation Technology is used in Neulasta®.
Nektar technology is used in Amgen's Neulasta® (pegfilgrastim), which is prescribed to reduce the risk of infection (initially marked by fever) in patients with some tumors receiving strong chemotherapy that decreases the number of infection-fighting white blood cells. Under the terms of an agreement between Nektar and Amgen, Nektar receives manufacturing revenues for Neulasta.
BAX 855, PEGylated rFVIII and other clotting proteins
Nektar's advanced polymer conjugate technology is used in two separate development collaborations with Baxter in Hemophilia.
Nektar and Baxter have two separate collaborations to develop novel therapeutics to treat hemophilia using Nektar's advanced polymer conjugate technologies. Under the agreements, Nektar is entitled to receive royalties on the global sales of these programs, in addition to contract research and manufacturing revenues. The lead program, BAX 855 (Longer-acting ADVATE) is a PEGylated recombinant FVIII molecule, which utilizes Nektar's proprietary PEGylation technology and Baxter's proprietary plasma and albumin free platform. The program is Baxter's most advanced longer-acting candidate, and has completed Phase 3 clinical development. Baxter intends to file a BLA in the U.S. before the end of 2014.
NKTR-061, the Amikacin Inhale drug-device combination product, is being developed in partnership with Bayer HealthCare.
Amikacin Inhale will be adjunctive therapy to the current antibiotic therapies administered intravenously as standard of care. The targeted aerosol delivery platform in NKTR-061 delivers antimicrobial agent directly to the site of infection in the lungs. The product can be integrated with conventional mechanical ventilators or used as a hand-held 'off-vent' device for patients no longer requiring breathing assistance. Under the terms of the agreement with Bayer, Nektar is entitled to receive up to $125 million in development milestones for Amikacin Inhale, as well as a flat 30% royalty on product sales in the U.S. and royalties of up to 25% on sales outside of the U.S.
Nektar and Ophthotech entered into an exclusive global licensing agreement for Fovista.
Fovista is an anti-platelet-derived growth factor (anti-PDGF) agent. Ophthotech is investigating Fovista administered in combination with anti-vascular endothelial growth factor (anti-VEGF) therapy for the treatment of neovascular age-related macular degeneration (wet AMD).
Nektar Proprietary PEGylation Technology is used by Pfizer for which Nektar receives manufacturing revenues.
Nektar Proprietary PEGylation Technology is used by Roche for which Nektar receives manufacturing revenues under a licensing agreement.
Nektar Proprietary PEGylation Technology is used in MIRCERA. Under a collaboration with Roche, Nektar receives royalties on global sales of MIRCERA.
Nektar Proprietary PEGylation Technology is used by Schering-Plough for PEG-INTRON which Nektar receives manufacturing revenues.
Nektar's proprietary conjugation technology is used in the novel antibody fragment through a collaboration with UCB.
Nektar technology is used in the antibody fragment, Cimzia® (certolizumab pegol). Cimzia® is the first and only PEGylated Fab' fragment of a humanized anti-TNF-alpha antibody approved by the FDA for Crohn's disease. The product is approved in the U.S. rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis and in the EU for rheumatoid arthritis. Under the terms of the agreement between Nektar and UCB, Nektar will receive manufacturing revenues and royalties on global sales of Cimzia® for all indications.
* MOVANTIK is a trademark of AstraZeneca; Neulasta® is a registered trademark of Amgen; SEMPRANA is a trademark and Tempo® is a registered trademark of Allergan, Inc.; Somavert® is a registered trademark of Pfizer; PEGASYS® and MIRCERA® are registered trademarks of F. Hoffmann-La Roche Ltd.; PEG-INTRON® is a registered trademark of Schering-Plough; Cimzia® is a registered trademark of UCB; Fovista® is a registered trademark of Ophthotech Corporation.
For more information, please contact our world-class business development team at .